Skip to main content
. 2023 Nov 9;16:923–935. doi: 10.2147/OTT.S427942

Table 1.

The Immune Checkpoint Inhibitors (ICIs) Information and Dosage

ICIs Trade Name Date of Approval Drug-Dose
Pembrolizumab Keytruda July 2018 200mg
Nivolumab Opdivo June 2018 240mg
Toripalimab TuoYi December 2018 240mg
Sintilimab Daboshu December 2018 200mg
Tislelizumab Baizean December 2019 200mg
Camrelizumab AiRuiKa May 2019 200mg

Abbreviation: ICIs, Immune checkpoint inhibitors.